Results 111 to 120 of about 4,942 (259)

PCSK9 Inhibitors in Secondary Prevention – An Opportunity for Personalized Therapy [PDF]

, 2020
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is the primary cause of ASCVD and reducing LDL-C levels with statin therapy significantly reduces ASCVD risk; however,
Board, Chase, Dixon, Dave L., Kelly, Michael S., Shapiro, Michael D.   +3 more
core   +1 more source

Efficacy and outcomes of inclisiran in the management of homozygous and heterozygous familial hypercholesterolemia: a systematic review and meta-analysis

Annals of Medicine and Surgery
Objective: To find out the efficacy of Inclisiran sodium in heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) patient groups.
Zaraq Khan, Ajeet Singh, Muhammad Haseeb Ur Rasool, Nimra Qasim, Muhammad Yafaa Naveed Chaudhary, Saif Syed, Monazza Riaz, Wajih Rehman, Ihtiham Rehman, R. Islam, Hamza Islam, Aqeel Muhammad, Raveena Devi, Calvin R. Wei, Farheen Naaz, Aymar Akilimali   +15 more
semanticscholar   +1 more source

INCLISIRAN: A SYSTEMATIC REVIEW OF THE BENEFITS OF PROMISING LIPID-LOWERING IN THE TREATMENT OF DYSLIPIDEMIAS

, 2022
Amanda Lima Souza, LUANA RODRIGUES PEREIRA, Yorrane Maxyme Alves de Souza, Michel De Oliveira Sanquite, Youmna Al Sayed, Lara Beltrame Spadoto, Alex Bruno Vilhalba Brunel, Antônio Alves Filho, Manuel Francisco de Araújo Lima, Regina kelly David Bezerra, Maria Carolaine Queiroz de Andrade   +10 more
openalex   +2 more sources

Management of dyslipidaemia in patients with comorbidities-facing the challenge [PDF]

This review aims to examine the evidence on the benefits and risks of lipid-lowering drugs in patients with liver disease. Elevated liver enzyme levels often lead to cautious discontinuation of these drugs, potentially withholding from patients their ...
Agewall S, Borghi C, Dobrev D, Drexel H, Fasching P, Frühwald L, Huber K, Kaski JC, Semb AG, Wassmann S   +9 more
core   +1 more source

Anti-interleukin-5 efficacy in an inclisiran-triggered eosinophilic myocarditis: a case report

European Heart Journal: Case Reports
Background Eosinophilic myocarditis is a rare condition that can be associated with hypersensitivity reactions. Endomyocardial biopsy (EMB) is required for diagnosis, especially when cardiac magnetic resonance (CMR) is inconclusive.
F. Tartaglia, Maria Rita Messina, Stefa Rizzo, Enrico Heffler, C. Panico   +4 more
semanticscholar   +1 more source

Inclisiran Usage in Very High-Risk Patients with Dyslipidemia Resistant to Statins and Ezetimibe Therapy

Український журнал серцево-судинної хірургії
Background. Complications of systemic atherosclerosis (myocardial infarction, ischemic stroke) are the main causes of mortality and disability in the modern world.
Є. Ю. Марушко, Г. Б. Маньковський, А. А. Левадська   +2 more
doaj   +1 more source

Inclisiran til hyperkolesterolæmi

Ugeskrift for Læger
In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects.
Todorovac, Nerma, Hansen, Michael Skov, Elpert, Frank-Peter   +2 more
openaire   +1 more source

Lipid Lowering Therapy: An Era Beyond Statins. [PDF]

, 2022
Dyslipidemia, specifically elevated LDL cholesterol levels, causes atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial infarction and stroke.
Abdul-Rahman, Toufik, Ahmad, Shahzaib, Awuah, Wireko Andrew, Bandyopadhyay, Dhrubajyoti, Bukhari, Syed Muhammad Awais, Capriles, Camilo Andrés Avendaño, Corriero, Anna, de Andrade, Heloisa, Goel, Akshay, Gupta, Rahul, MD, Hajra, Adrija, Herrera, Emiliano Cantu, Lawrence, Jannel, Mares, Adriana C, Patel, Neal, Shah, Rohan, Shaikh, Raheel, Ulusan, Sebahat   +17 more
core   +1 more source

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential

Therapeutics and Clinical Risk Management, 2020
Constantine E Kosmas,1 Alba Muñoz Estrella,2 Andreas Skavdis,3 Edilberto Peña Genao,4 Ian Martinez,5 Eliscer Guzman1 1Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA; 2Department of Medicine, Mount ...
Kosmas CE, Muñoz Estrella A, Skavdis A, Peña Genao E, Martinez I, Guzman E   +5 more
doaj  

468 Cost-Effectiveness Analysis of Inclisiran as Add-On Lipid-Lowering Therapy for Patients With Cardiovascular Disease [PDF]

, 2020
Ning Kam, Kanila Perera, Ella Zomer, Danny Liew, Zanfina Ademi   +4 more
openalex   +1 more source